Organoids Services Market Strategies, Top Players, Growth Opportunities, Analysis and Forecast by 2031

The organoids services market size is projected to reach US$ 15.01 billion by 2031 from US$ 3.03 billion in 2023. The market is expected to register a CAGR of 22.3% in 2023–2031. The integration of artificial intelligence is likely to act as one of the key trends in the organoids services market in the future.

Organoids Services Market Analysis

Factors contributing to the organoids services market growth include the rising demand for novel drug screening services, and an upsurge in the popularity of customized medications. However, the dearth of skilled professionals and stringent safety regulations hamper the market growth.

Organoids Services Market Overview

Organoids are emerging as a powerful asset for researchers and drug developers as they seek more efficient and accurate methods to identify promising drug candidates and predict their efficacy. The ability to generate patient-derived organoids (PDOs) opens up exciting possibilities for personalized drug screening. Organoids serve as realistic and relevant models for drug screening compared to traditional 2D cell cultures. They mimic the complexity of human organs, including their cellular composition, structure, and function, providing a more accurate representation of drug responses in the human body. This enables researchers to identify potential drug candidates more confidently, and avoid costly and time-consuming setbacks in clinical trials. The organoid services market is experiencing rapid growth owing to the increasing demand for innovative screening services.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Organoids Services Market: Strategic Insights

Organoids Services Market

• 
  CAGR (2023 - 2031)

  22.3%
• Market Size 2023
  US$ 3.03 Billion
• Market Size 2031
  US$ 15.01 Billion

Market Dynamics

GROWTH DRIVERS

• The organoid services market is experiencing rapid growth owing to the increasing demand for innovative screening services

FUTURE TRENDS

• AI-driven automation can revolutionize organoid production and research workflows

OPPORTUNITIES

• Increasing key developments, launches, and strategic collaborations among market players create ample opportunities for the organoid services market growth

Key Players

• Sino Biological Inc.;
• Eurofins Scientific SE;
• Molecular Devices, LLC.;
• InSphero;
• Cyprio; InnoSer;
• LABTOO;
• CUSABIO TECHNOLOGY LLC;
• Oncodesign Services;
• HUB Organoids B.V. (Hubrecht Organoid Technology)

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Type

• Intestine
• Liver
• Stomach
• Pancreas
• Lung
• Brain
• Kidney

Application

• Developmental Biology Disease
• Pathology of Infectious Disease
• Regenerative Medicine
• Drug Toxicity & Efficacy Testing
• Drug Discovery & Personalized Medicine

Source

• Pluripotent Stem Cells
• Organ Specific Adult Stem Cell

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Organoids Services Market Drivers and Opportunities

Surge in Popularity of Personalized Drugs Favors Organoids Services Market

Personalized or precision medicine is the study of practices or drugs tailored to the individual patient based on the projected response or disease risk. According to a study released by the Personalized Medicine Coalition (PMC), the share of personalized medication approvals in total FDA approvals for new molecular entities rose from 5% in 2005 to over 25% in 2016. Further, 73% of compounds in the pipeline are potential oncological candidates, and 42% have the potential to be personalized therapies. Biopharmaceutical companies have virtually doubled their R&D investments in personalized pharmaceuticals. Further, in the coming years, this spending is expected to surge by 33%. Moreover, researchers in the field of biopharmaceuticals anticipate a 69% rise in the creation of customized medications during the said period. As per the most recent study published in the PMC in 2021, the number of customized medications available in the US market has jumped up from 132 in 2016 to 286 in 2020. The information was produced by tracking the PMC's numbers for personalized medication since 2008. The use of organoids to produce customized medication regimens holds significant prospects for enhancing patient care. With their active efforts to promote and raise awareness of precision medicine, pharmacists play a crucial role in driving up demand for customized medications. According to a recent published in one of the NCBI journals in 2021, more than 50% of consumers preferred to buy customized goods or services. These stats indicate the build up of a conducive environment for the growth of the organoids services market.

Key Developments by Companies to Create Opportunities for Organoids Services Market Growth

The progress of the healthcare sector has led to a rise in the demand for organoids across the world. This increased demand contributes to new product developments, acquisitions, partnerships, product launches, and approvals on a global level. Major market players are involved in activities to ensure the innovation and development of efficient services and products. A few of the recent key developments are listed below:

• In June 2024, Molecular Devices, LLC. formally opened its purpose-built facility in Cardiff, UK. The multimillion-pound facility was designed to accommodate the exclusive bioprocess workflow and innovative bioreactor technology of the business, allowing for the large-scale, quality-controlled production of PDOs. Substantial amounts of repeatable PDOs that are 3D-ready are available as a custom service and are cryopreserved in a manner that is ready for analysis. Researchers can defrost, plate, and use these products when needed.
• In January 2024, HUB Organoids (HUB) launched IntegriGut Screen services for the global market. This screening service employs IBD PDO monolayers to aid in the development of novel IBD therapies by ensuring the availability of high-quality human data on epithelial barrier function.
• In July 2023, Molecular Devices launched a custom organoid line expansion service with unique bioprocess technology for high-throughput applications.

• In July 2023, Molecular Devices launched a custom organoid line expansion service with unique bioprocess technology for high-throughput applications.
• In February 2023, Molecular Devices, LLC., and HUB Organoids (HUB) announced a strategic collaboration to contribute to the continued development of next-generation 3D biology technologies that enable step-change reduction in preclinical to clinical drug attrition.

Such key developments, launches, and strategic collaborations create ample opportunities for the organoid services market growth.

Organoids Services Market Report Segmentation Analysis

Key segments that contributed to the derivation of the organoids services market analysis are product, application, source, and manufacturing.

• Based on type, the organoids services market is classified into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine segment held the largest share of the market in 2023, and it is further anticipated to register the highest CAGR during the forecast period.
• By application, the market is segmented into developmental biology, infectious disease pathology, regenerative medicine, drug toxicity & efficacy testing, drug discovery & personalized medicine, and others. The developmental biology disease segment held the largest share of the market in 2023; it is further anticipated to register the highest CAGR during 2023–2031.
• Based on source, the organoids services market is divided into pluripotent stem cells and organ-specific adult stem cells. The pluripotent stem cells segment held a larger share of the market in 2023. The pluripotent stem cells segment is anticipated to register a higher CAGR during the forecast period.

Organoids Services Market Share Analysis by Geography

The geographic scope of the organoids services market report is mainly divided into five regions: North America, Asia Pacific, Europe, and the Middle East & Africa.

North America dominates the organoids services market. Market players in the US are focusing on organic growth strategies to strengthen their foothold. In February 2023, Molecular Devices, LLC. and HUB Organoids (HUB) announced a strategic collaboration to continue the development of next-generation 3D biology technologies that drive step-change reduction in preclinical to clinical drug attrition. Further, increasing research and development activities, rising demand for tissue engineering and organ transplantation, and a high rate of organoid adoption are driving the organoid services market in the country. Organoids have the potential to overcome several previous limitations associated with biomedical research studies, with a high focus on making mechanistic insights on human development available for researchers, producing accurate models of human disease, and generating patient-matched tissue sources for regenerative medicine. Asia Pacific is anticipated to record the highest CAGR during 2023–2031.

Organoids Services Market Report Scope

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Organoids Services Market News and Recent Developments

The organoids services market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the market are listed below:

• InSphero, a biotech company, signed a partnership agreement with Genome Biologics, Frankfurt. In this partnership, InSphero will receive the exclusive global rights to commercialize Genome Biologics' 3D Cardiac Organoid Platform. The platform provides accurate, scalable, and disease-specific organoid models for creating novel treatments, placing it at the forefront of heart disease research. (InSphero, Press Release, May 2024)

Organoids Services Market Report Coverage and Deliverables

The "Organoids Services Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:

• Organoids services market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Organoids services market trends as well as market dynamics such as drivers, restraints, and key opportunities
• Detailed PEST/Porter's Five Forces and SWOT analysis
• Organoids services market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments.
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the organoids services market
• Detailed company profiles